Drug interactions
Lapatinib + Liposomal doxorubicin
Severity: Moderate
Lapatinib and Liposomal doxorubicin: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Lapatinib inhibits P-glycoprotein and CYP3A4 and may increase doxorubicin exposure. Both drugs are linked to cardiac toxicity such as reduced LVEF, so overlapping toxicity matters.
What this interaction means in plain words
Lapatinib and Liposomal doxorubicin can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Lapatinib belongs to Oncology; Liposomal doxorubicin belongs to Oncology.
Why it happens
P-glycoprotein and CYP3A4 inhibition by lapatinib, plus additive cardiotoxicity.
What to do
Monitor LVEF at baseline and periodically, and monitor blood counts. Reduce the doxorubicin dose if toxicity occurs.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Lapatinib and Liposomal doxorubicin, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Liposomal doxorubicin
- Dengue vaccine + Liposomal doxorubicin Contraindicated
- Belatacept + Liposomal doxorubicin Major
- Cyclosporine + Liposomal doxorubicin Major
- Dronedarone + Liposomal doxorubicin Major
- Elvitegravir / cobicistat / emtricitabine / tenofovir df + Liposomal doxorubicin Major
- Fingolimod + Liposomal doxorubicin Major
Other interactions of Lapatinib
- Dofetilide + Lapatinib Contraindicated
- Ibutilide + Lapatinib Contraindicated
- Lapatinib + Pimozide Contraindicated
- Lapatinib + Saquinavir Contraindicated
- Lapatinib + Thioridazine Contraindicated
- Adagrasib + Lapatinib Major
Frequently asked questions
Can I take Lapatinib with Liposomal doxorubicin?
MediHelp rates the interaction as moderate. Lapatinib and Liposomal doxorubicin can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Lapatinib inhibits P-glycoprotein and CYP3A4 and may increase doxorubicin exposure. Both drugs are linked to cardiac toxicity such as reduced LVEF, so overlapping toxicity matters.
How serious is the interaction between Lapatinib and Liposomal doxorubicin?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor LVEF at baseline and periodically, and monitor blood counts. Reduce the doxorubicin dose if toxicity occurs.
What other medicines interact with Liposomal doxorubicin?
MediHelp also lists interactions of Liposomal doxorubicin with, for example, Dengue vaccine, Belatacept, Cyclosporine. The full list is on the Liposomal doxorubicin page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
